523 related articles for article (PubMed ID: 11258776)
1. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration.
Breslin TM; Hess KR; Harbison DB; Jean ME; Cleary KR; Dackiw AP; Wolff RA; Abbruzzese JL; Janjan NA; Crane CH; Vauthey JN; Lee JE; Pisters PW; Evans DB
Ann Surg Oncol; 2001 Mar; 8(2):123-32. PubMed ID: 11258776
[TBL] [Abstract][Full Text] [Related]
2. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas.
Spitz FR; Abbruzzese JL; Lee JE; Pisters PW; Lowy AM; Fenoglio CJ; Cleary KR; Janjan NA; Goswitz MS; Rich TA; Evans DB
J Clin Oncol; 1997 Mar; 15(3):928-37. PubMed ID: 9060530
[TBL] [Abstract][Full Text] [Related]
3. Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma.
Pisters PW; Abbruzzese JL; Janjan NA; Cleary KR; Charnsangavej C; Goswitz MS; Rich TA; Raijman I; Wolff RA; Lenzi R; Lee JE; Evans DB
J Clin Oncol; 1998 Dec; 16(12):3843-50. PubMed ID: 9850029
[TBL] [Abstract][Full Text] [Related]
4. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?
Crane CH; Abbruzzese JL; Evans DB; Wolff RA; Ballo MT; Delclos M; Milas L; Mason K; Charnsangavej C; Pisters PW; Lee JE; Lenzi R; Vauthey JN; Wong AB; Phan T; Nguyen Q; Janjan NA
Int J Radiat Oncol Biol Phys; 2002 Apr; 52(5):1293-302. PubMed ID: 11955742
[TBL] [Abstract][Full Text] [Related]
5. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience.
Yeo CJ; Abrams RA; Grochow LB; Sohn TA; Ord SE; Hruban RH; Zahurak ML; Dooley WC; Coleman J; Sauter PK; Pitt HA; Lillemoe KD; Cameron JL
Ann Surg; 1997 May; 225(5):621-33; discussion 633-6. PubMed ID: 9193189
[TBL] [Abstract][Full Text] [Related]
6. Preoperative chemoradiation for patients with pancreatic cancer: toxicity of endobiliary stents.
Pisters PW; Hudec WA; Lee JE; Raijman I; Lahoti S; Janjan NA; Rich TA; Crane CH; Lenzi R; Wolff RA; Abbruzzese JL; Evans DB
J Clin Oncol; 2000 Feb; 18(4):860-7. PubMed ID: 10673529
[TBL] [Abstract][Full Text] [Related]
7. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head.
Evans DB; Varadhachary GR; Crane CH; Sun CC; Lee JE; Pisters PW; Vauthey JN; Wang H; Cleary KR; Staerkel GA; Charnsangavej C; Lano EA; Ho L; Lenzi R; Abbruzzese JL; Wolff RA
J Clin Oncol; 2008 Jul; 26(21):3496-502. PubMed ID: 18640930
[TBL] [Abstract][Full Text] [Related]
8. Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas.
Mehta VK; Fisher G; Ford JA; Poen JC; Vierra MA; Oberhelman H; Niederhuber J; Bastidas JA
J Gastrointest Surg; 2001; 5(1):27-35. PubMed ID: 11309645
[TBL] [Abstract][Full Text] [Related]
9. Preoperative chemoradiation for patients with locally advanced adenocarcinoma of the pancreas.
White R; Lee C; Anscher M; Gottfried M; Wolff R; Keogan M; Pappas T; Hurwitz H; Tyler D
Ann Surg Oncol; 1999; 6(1):38-45. PubMed ID: 10030414
[TBL] [Abstract][Full Text] [Related]
10. Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial.
Versteijne E; Suker M; Groothuis K; Akkermans-Vogelaar JM; Besselink MG; Bonsing BA; Buijsen J; Busch OR; Creemers GM; van Dam RM; Eskens FALM; Festen S; de Groot JWB; Groot Koerkamp B; de Hingh IH; Homs MYV; van Hooft JE; Kerver ED; Luelmo SAC; Neelis KJ; Nuyttens J; Paardekooper GMRM; Patijn GA; van der Sangen MJC; de Vos-Geelen J; Wilmink JW; Zwinderman AH; Punt CJ; van Eijck CH; van Tienhoven G;
J Clin Oncol; 2020 Jun; 38(16):1763-1773. PubMed ID: 32105518
[TBL] [Abstract][Full Text] [Related]
11. Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome.
Pisters PW; Wolff RA; Janjan NA; Cleary KR; Charnsangavej C; Crane CN; Lenzi R; Vauthey JN; Lee JE; Abbruzzese JL; Evans DB
J Clin Oncol; 2002 May; 20(10):2537-44. PubMed ID: 12011133
[TBL] [Abstract][Full Text] [Related]
12. Chemoradiotherapy with gemcitabine and continuous 5-FU in patients with primary inoperable pancreatic cancer.
Wilkowski R; Thoma M; Bruns C; Wagner A; Heinemann V
JOP; 2006 Jul; 7(4):349-60. PubMed ID: 16832132
[TBL] [Abstract][Full Text] [Related]
13. Surgical resection after preoperative chemoradiotherapy benefits selected patients with unresectable pancreatic cancer.
Aristu J; Cañón R; Pardo F; Martínez-Monge R; Martin-Algarra S; Manuel Ordoñez J; Villafranca E; Moreno M; Cambeiro M; Azinovic I
Am J Clin Oncol; 2003 Feb; 26(1):30-6. PubMed ID: 12576921
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors and adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma.
You DD; Lee HG; Heo JS; Choi SH; Choi DW
J Gastrointest Surg; 2009 Sep; 13(9):1699-706. PubMed ID: 19582512
[TBL] [Abstract][Full Text] [Related]
15. Preoperative chemoradiation for adenocarcinoma of the pancreas: excessive toxicity of prophylactic hepatic irradiation.
Evans DB; Abbruzzese JL; Cleary KR; Buchholz DJ; Fenoglio CJ; Collier C; Rich TA
Int J Radiat Oncol Biol Phys; 1995 Nov; 33(4):913-8. PubMed ID: 7591902
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant therapy in pancreatic cancer: Phase I trial of radiation dose escalation with concurrent full-dose gemcitabine.
Allen AM; Zalupski MM; Robertson JM; Eckhauser FE; Simone D; Brown D; Hejna G; Normolle D; Lawrence TS; McGinn CJ
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1461-7. PubMed ID: 15275733
[TBL] [Abstract][Full Text] [Related]
17. Impact of preoperative chemoradiotherapy on survival in patients with resectable pancreatic cancer.
Vento P; Mustonen H; Joensuu T; Kärkkäinen P; Kivilaakso E; Kiviluoto T
World J Gastroenterol; 2007 Jun; 13(21):2945-51. PubMed ID: 17589944
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study.
Hsu CC; Herman JM; Corsini MM; Winter JM; Callister MD; Haddock MG; Cameron JL; Pawlik TM; Schulick RD; Wolfgang CL; Laheru DA; Farnell MB; Swartz MJ; Gunderson LL; Miller RC
Ann Surg Oncol; 2010 Apr; 17(4):981-90. PubMed ID: 20087786
[TBL] [Abstract][Full Text] [Related]
19. Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer.
Ohigashi H; Ishikawa O; Eguchi H; Takahashi H; Gotoh K; Yamada T; Yano M; Nakaizumi A; Uehara H; Tomita Y; Nishiyama K
Ann Surg; 2009 Jul; 250(1):88-95. PubMed ID: 19561477
[TBL] [Abstract][Full Text] [Related]
20. Phase 2 Study of Neoadjuvant Treatment of Sequential S-1-Based Concurrent Chemoradiation Therapy Followed by Systemic Chemotherapy with Gemcitabine for Borderline Resectable Pancreatic Adenocarcinoma (HOPS-BR 01).
Hayashi T; Nakamura T; Kimura Y; Yoshida M; Someya M; Kawakami H; Sakuhara Y; Katoh N; Takahashi K; Ambo Y; Miura K; Motoya M; Tanaka E; Murakawa K; Yamabuki T; Yamazaki H; Katanuma A; Hirano S;
Int J Radiat Oncol Biol Phys; 2019 Nov; 105(3):606-617. PubMed ID: 31306735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
